BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 9156662)

  • 1. Serum levels of TNF, IL-6 and sCD23 correlate with changes in lymphocyte count in patients with B-cell chronic lymphocytic leukaemia receiving interferon-alpha therapy.
    Jewell AP; Worman CP; Giles FJ; Goldstone AH
    Leuk Lymphoma; 1997 Jan; 24(3-4):327-33. PubMed ID: 9156662
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating levels of cytokines and soluble cytokine receptors in various T-cell malignancies.
    Raziuddin S; Sheikha A; Abu-Eshy S; al-Janadi M
    Cancer; 1994 May; 73(9):2426-31. PubMed ID: 8168046
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble CD23 reliably reflects disease activity in B-cell chronic lymphocytic leukemia.
    Reinisch W; Willheim M; Hilgarth M; Gasché C; Mader R; Szepfalusi S; Steger G; Berger R; Lechner K; Boltz-Nitulescu G
    J Clin Oncol; 1994 Oct; 12(10):2146-52. PubMed ID: 7931486
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic importance of soluble CD23 in B-cell chronic lymphocytic leukemia.
    Saka B; Aktan M; Sami U; Oner D; Sanem O; Dinçol G
    Clin Lab Haematol; 2006 Feb; 28(1):30-5. PubMed ID: 16430457
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Soluble CD23 and other receptors (CD4, CD8, CD25, CD71) in serum of patients with chronic lymphocytic leukemia.
    Beguin Y; Lampertz S; De Groote D; Igot D; Malaise M; Fillet G
    Leukemia; 1993 Dec; 7(12):2019-25. PubMed ID: 8255102
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Regulation of cytokine production by soluble CD23: costimulation of interferon gamma secretion and triggering of tumor necrosis factor alpha release.
    Armant M; Ishihara H; Rubio M; Delespesse G; Sarfati M
    J Exp Med; 1994 Sep; 180(3):1005-11. PubMed ID: 8064221
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low-dose "natural" alpha-interferon in B-cell derived chronic lymphocytic leukemia.
    Pozzato G; Franzin F; Moretti M; Tulissi P; Pecorari P; Melato M; Zacchi T; Evangelisti P; Campanacci L
    Haematologica; 1992; 77(5):413-7. PubMed ID: 1483591
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proliferative response of B chronic lymphocytic leukemia lymphocytes stimulated with IL2 and soluble CD23.
    Brizard A; Morel F; Lecron JC; Dreyfus B; Brizard F; Barra A; Preud'homme JL
    Leuk Lymphoma; 1994 Jul; 14(3-4):311-8. PubMed ID: 7950920
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prognostic importance of serum soluble CD23 level in chronic lymphocytic leukemia.
    Sarfati M; Chevret S; Chastang C; Biron G; Stryckmans P; Delespesse G; Binet JL; Merle-Beral H; Bron D
    Blood; 1996 Dec; 88(11):4259-64. PubMed ID: 8943862
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Serum levels of soluble CD23, but not soluble CD25, predict disease progression in early stage B-cell chronic lymphocytic leukemia.
    Knauf WU; Langenmayer I; Ehlers B; Mohr B; Adorf D; Nerl CH; Hallek M; Zwingers TH; Emmerich B; Thiel E
    Leuk Lymphoma; 1997 Nov; 27(5-6):523-32. PubMed ID: 9477135
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of interferon alpha on autocrine growth factor loops in B lymphoproliferative disorders.
    Heslop HE; Bianchi AC; Cordingley FT; Turner M; Chandima W; De Mel CP; Hoffbrand AV; Brenner MK
    J Exp Med; 1990 Dec; 172(6):1729-34. PubMed ID: 2258703
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment strategies for early-stage chronic lymphocytic leukemia: can interferon-inducible MxA protein and tumor necrosis factor play a role as predictive markers for response to interferon therapy?
    Bezares F; Kohan S; Sacerdote de Lustig E; Farías E; Murro H; Horisberger MA
    J Interferon Cytokine Res; 1996 Jul; 16(7):501-5. PubMed ID: 8836914
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinico-biological implications of increased serum levels of interleukin-8 in B-cell chronic lymphocytic leukemia.
    Molica S; Vitelli G; Levato D; Levato L; Dattilo A; Gandolfo GM
    Haematologica; 1999 Mar; 84(3):208-11. PubMed ID: 10189383
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of sIL2R, sCD23, sICAM-1, IL6 and sCD 14 serum levels in B-cell chronic lymphocytic leukemia.
    Callea V; Morabito F; Luise F; Piromalli A; Filangeri M; Stelitano C; Iacopino P; Nobile F; Brugiatelli M
    Haematologica; 1996; 81(4):310-5. PubMed ID: 8870374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Serum macrophage colony-stimulating factor (M-CSF) levels correlate with clinical response to interferon-alpha in patients with early-stage B-CLL.
    Jewell AP; Yong KL; Worman CP; Tsakona CP; Giles FJ; Goldstone AH
    Br J Haematol; 1994 Feb; 86(2):441-3. PubMed ID: 8199046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis.
    Molica S; Levato D; Dell'Olio M; Matera R; Minervini M; Dattilo A; Carotenuto M; Musto P
    Haematologica; 1996; 81(5):428-33. PubMed ID: 8952156
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of alpha-interferon and steroids on CD23 expression and release in B-cell chronic lymphocytic leukemia.
    Pozzato G; de Paoli P; Franzin F; Tulissi P; Moretti M; Basaglia G; Santini GF
    Haematologica; 1994; 79(3):205-12. PubMed ID: 7926968
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recombinant interferon alfa 2a in the treatment of patients with early stage B chronic lymphocytic leukaemia.
    McSweeney EN; Giles FJ; Worman CP; Jewel AP; Tsakona CP; Hoffbrand AV; Mehta AB; Newland AC; Cawley JC; Galvani D
    Br J Haematol; 1993 Sep; 85(1):77-83. PubMed ID: 8251412
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CD23 antigen regulation and signaling in chronic lymphocytic leukemia.
    Fournier S; Delespesse G; Rubio M; Biron G; Sarfati M
    J Clin Invest; 1992 Apr; 89(4):1312-21. PubMed ID: 1532590
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differentiation and activation antigens on blood mononuclear cells in lymphocytic leukemia before and during IFN-alpha 2B therapy.
    Demeter J; Paloczi K; Bibok G; Lehoczky D
    Leukemia; 1992; 6 Suppl 3():41S-45S. PubMed ID: 1602826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.